Literature DB >> 16242828

Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion.

Andrea L O Hebb1, Jean-François Poulin, Sean P Roach, Robert M Zacharko, Guy Drolet.   

Abstract

It is well documented that stressful life experiences contribute to the etiology of human mood disorders. Cholecystokinin (CCK) is a neuropeptide found in high concentrations throughout the central nervous system, where it is involved in numerous physiological functions. A role for CCK in the induction and persistence of anxiety and major depression appears to be conspicuous. While increased CCK has been associated with motivational loss, anxiety and panic attacks, an increase in mesocorticolimbic opioid availability has been associated with coping and mood elevation. The close neuroanatomical distribution of CCK with opioid peptides in the limbic system suggests that there may be an opioid-CCK link in the modulation and expression of anxiety or stressor-related behaviors. In effect, while CCK induces relatively protracted behavioral disturbances in both animal and human subjects following stressor applications, opioid receptor activation may change the course of psychopathology. The antagonistic interaction of CCK and opioid peptides is evident in psychological disturbances as well as stress-induced analgesia. There appears to be an intricate balance between the memory-enhancing and anxiety-provoking effects of CCK on one hand, and the amnesic and anxiolytic effects of opioid peptides on the other hand. Potential anxiogenic and mnemonic influences of site-specific mesocorticolimbic CCK and opioid peptide availability, the relative contributions of specific CCK and opioid receptors, as well as the time course underlying neuronal substrates of long-term behavioral disturbances as a result of stressor manipulations, are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242828     DOI: 10.1016/j.pnpbp.2005.08.008

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  29 in total

1.  Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors.

Authors:  Fabrizio Benedetti; Martina Amanzio; Wilma Thoen
Journal:  Psychopharmacology (Berl)       Date:  2010-10-08       Impact factor: 4.530

2.  Effect of the Combination of CI-988 and Morphine on Neuropathic Pain after Spinal Cord Injury in Rats.

Authors:  Junesun Kim; Youngkyung Kim; Suk-Chan Hahm; Young Wook Yoon
Journal:  Korean J Physiol Pharmacol       Date:  2015-02-25       Impact factor: 2.016

3.  Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice.

Authors:  C Del Boca; P E Lutz; J Le Merrer; P Koebel; B L Kieffer
Journal:  Neuroscience       Date:  2012-05-18       Impact factor: 3.590

Review 4.  Placebo mechanisms across different conditions: from the clinical setting to physical performance.

Authors:  Antonella Pollo; Elisa Carlino; Fabrizio Benedetti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-06-27       Impact factor: 6.237

Review 5.  How placebos change the patient's brain.

Authors:  Fabrizio Benedetti; Elisa Carlino; Antonella Pollo
Journal:  Neuropsychopharmacology       Date:  2010-06-30       Impact factor: 7.853

6.  Stress impairs GABAergic network function in the hippocampus by activating nongenomic glucocorticoid receptors and affecting the integrity of the parvalbumin-expressing neuronal network.

Authors:  Wen Hu; Mingyue Zhang; Boldizsár Czéh; Gabriele Flügge; Weiqi Zhang
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

Review 7.  Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.

Authors:  Marc J Berna; Jose A Tapia; Veronica Sancho; Robert T Jensen
Journal:  Curr Opin Pharmacol       Date:  2007-11-09       Impact factor: 5.547

8.  Enkephalin knockdown in the basolateral amygdala reproduces vulnerable anxiety-like responses to chronic unpredictable stress.

Authors:  Patrick Bérubé; Jean-François Poulin; Sylvie Laforest; Guy Drolet
Journal:  Neuropsychopharmacology       Date:  2013-11-11       Impact factor: 7.853

Review 9.  Neuropeptides in depression: role of VGF.

Authors:  Smita Thakker-Varia; Janet Alder
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

10.  The effect of opioid receptor blockade on the neural processing of thermal stimuli.

Authors:  Eszter D Schoell; Ulrike Bingel; Falk Eippert; Juliana Yacubian; Kerrin Christiansen; Hilke Andresen; Arne May; Christian Buechel
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.